Have a feature idea you'd love to see implemented?
Let us know!
RLMD Relmada Therapeutics Inc
Price (delayed)
$3.63
Market cap
$109.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.87
Enterprise value
$107.45M
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed
Highlights
Relmada Therapeutics's net income has increased by 33% YoY and by 8% QoQ
The EPS has grown by 33% YoY and by 8% from the previous quarter
The quick ratio has contracted by 33% YoY but it has grown by 9% from the previous quarter
RLMD's equity is down by 45% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of RLMD
Market
Valuations
Earnings
Shares outstanding
30.17M
Market cap
$109.53M
Enterprise value
$107.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$86.76M
EBITDA
-$86.76M
Free cash flow
-$48.18M
Per share
Balance sheet
Liquidity
EPS
-$2.87
Free cash flow per share
-$1.6
Book value per share
$2.04
Revenue per share
$0
TBVPS
$2.35
Total assets
$71.03M
Total liabilities
$9.54M
Debt
$0
Equity
$61.49M
Working capital
$61.44M
Debt to equity
0
Current ratio
7.44
Quick ratio
7.39
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-95.8%
Return on equity
-108.6%
Return on invested capital
-113.6%
Return on capital employed
-141.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RLMD stock price
How has the Relmada Therapeutics stock price performed over time
Intraday
0.97%
1 week
4.01%
1 month
4.91%
1 year
20.2%
YTD
-12.32%
QTD
12.04%
Financial performance
How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$91.33M
Net income
-$86.76M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's net income has increased by 33% YoY and by 8% QoQ
Relmada Therapeutics's operating income has increased by 31% YoY and by 7% from the previous quarter
Growth
What is Relmada Therapeutics's growth rate over time
Valuation
What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
1.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 33% YoY and by 8% from the previous quarter
The P/B is 48% less than the 5-year quarterly average of 3.4 but 27% more than the last 4 quarters average of 1.4
RLMD's equity is down by 45% YoY and by 15% from the previous quarter
Efficiency
How efficient is Relmada Therapeutics business performance
Relmada Therapeutics's return on equity has decreased by 14% YoY and by 6% QoQ
The ROA has declined by 11% year-on-year and by 4.9% since the previous quarter
RLMD's return on invested capital is down by 3.3% since the previous quarter
Dividends
What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RLMD.
Financial health
How did Relmada Therapeutics financials performed over time
Relmada Therapeutics's total assets has decreased by 42% YoY and by 16% QoQ
The company's current ratio fell by 35% YoY but it rose by 9% QoQ
RLMD's debt is 100% smaller than its equity
RLMD's equity is down by 45% YoY and by 15% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.